Lessons from phase III-trials on the hormonal treatment of prostatic cancer. I: Results of EORTC-trials 30761 and 30762.
de Voogt
H J
HJ
Department of Urology, Free University Hospital, Amsterdam, Netherlands.
Pavone-Macaluso
M
M
Smith
P H
PH
de Pauw
M
M
Suciu
S
S
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy* / Q000401:mortality; D002986:Clinical Trials as Topic; D003534:Cyproterone / Q000031:analogs & derivatives / Q000627:therapeutic use; D017373:Cyproterone Acetate; D004054:Diethylstilbestrol / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004961:Estramustine / Q000627:therapeutic use; D005060:Europe; D006801:Humans; D008297:Male; D008525:Medroxyprogesterone / Q000031:analogs & derivatives / Q000627:therapeutic use; D017258:Medroxyprogesterone Acetate; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality; D011897:Random Allocation
D000970:Antineoplastic Agents; D004961:Estramustine; D017373:Cyproterone Acetate; D004054:Diethylstilbestrol; D017258:Medroxyprogesterone Acetate; D003534:Cyproterone; D008525:Medroxyprogesterone